UTILITY Therapeutics
A biotech company developing Pivmecillinam for the treatment of urinary tract infections (UTI).
Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI). Mecillinam, an intravenous (IV) formulation, is being developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting.
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze